<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Allena Pharmaceuticals, Inc.

    Allena Pharmaceuticals, Inc.

    Allena’s lead product candidate, reloxaliase, is a first-in-class, oral enzyme t...

    Allena’s lead product candidate, reloxaliase,...

    Filing Type:    PU
    Axsome Therapeutics, Inc.

    Axsome Therapeutics, Inc.

    Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing...

    Axsome Therapeutics, Inc. is a clinical-stage b...

    Filing Type:    PU
    Champions Oncology, Inc.

    Champions Oncology, Inc.

    Champions Oncology, Inc. is engaged in the development of advanced technology solu...

    Champions Oncology, Inc. is engaged in the deve...

    Filing Type:    PU
    Establishment Labs Holdings Inc.

    Establishment Labs Holdings Inc.

    Establishment Labs is a global medical technology company focused on improving pat...

    Establishment Labs is a global medical technolo...

    Filing Type:    PU
    Inogen, Inc

    Inogen, Inc

    Inogen’s mission to improve the quality of life of supplemental oxygen users beg...

    Inogen’s mission to improve the quality of li...

    Filing Type:    PU
    Cidara Therapeutics, Inc.

    Cidara Therapeutics, Inc.

    Cidara is a clinical-stage biotechnology company focused on the discovery, develop...

    Cidara is a clinical-stage biotechnology compan...

    Filing Type:    PU
    TCR2 Therapeutics Inc.

    TCR2 Therapeutics Inc.

    TCR² is an innovative immunotherapy company developing the next generation of T c...

    TCR² is an innovative immunotherapy company de...

    Filing Type:    PU
    IMV Inc.

    IMV Inc.

    IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...

    IMV Inc. is a clinical stage biopharmaceutical ...

    Filing Type:    PU
    Neoleukin Therapeutics, Inc.

    Neoleukin Therapeutics, Inc.

    Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...

    Neoleukin is a biopharmaceutical company creati...

    Filing Type:    PU
    Turning Point Therapeutics, Inc.

    Turning Point Therapeutics, Inc.

    Turning Point Therapeutics is a clinical-stage precision oncology company with a p...

    Turning Point Therapeutics is a clinical-stage ...

    Filing Type:    PU
    Tiziana Life Sciences plc

    Tiziana Life Sciences plc

    Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...

    Tiziana Life Sciences is a dual-listed (NASDAQ:...

    Filing Type:    PU
    MacroGenics, Inc.

    MacroGenics, Inc.

    MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...

    MacroGenics is a clinical-stage biopharmaceutic...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.